Latest: FDA Approves New Biosimilar for Oncology Treatment
Neurology

Phase 2 GABriella Study Represents First Step in Testing Selective Novel Y-Secretase Modulators for Prodromal Alzheimer Disease

by Neurology Live
0 Comments
0 Mins
Researchers unveil promising findings from the GABriella trial, exploring a novel treatment for prodromal Alzheimer's disease at AAIC 2025.
Tags:
Neurology Live
Author

Neurology Live

Previous Post
Better Medicine Raises $7M to Commercialize AI-Powered Radiology Tools
Next Post
Can a computer turn our internal monologue into speech?
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago